CarlsmedvsJohnson & Johnson

CARL and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CARL

Carlsmed, Inc.

$17.25

Value $461M

-0.69%
CARL's page

Carlsmed (CARL) has a market value of $461M and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, CARL moved +40.8% and JNJ +36.6%. Dividend yield: CARL none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CARL$461M

    JNJ$644B

    JNJ is 1,397 times CARL

  • Revenue, 12 months

    CARL$72M

    JNJ$99.3B

    JNJ is 1,384 times CARL

  • Net income, 12 months

    CARL-$40M

    JNJ$16.1B

  • Operating margin

    CARL-59.0%

    JNJ–

  • ROIC

    CARL-31.3%

    JNJ12.4%

    43.7 points apart

  • P/E

    CARL–

    JNJ40.0

  • Dividend yield

    CARL0.0%

    JNJ2.0%

    2.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CARL+40.8%

JNJ+36.6%

75100125DecFebAprJunAugOct
Returns by period
PeriodCARLWith dividendsJNJWith dividends
1 year since November 18, 2025+40.8%Price +40.8%+36.6%Price +33.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CARLCarlsmedJNJJohnson & Johnson

Valuation

CARLJNJ
Valuation
Price$17.25$267.31
Market value$461M$644B
Enterprise value (EV)$417M$672B
P/E–40.0
P/E, 5-year median–21.9
P/B6.17.9
EV/EBIT–37.9
Free cash flow yield–3.2%

Results and growth

CARLJNJ
Results and growth
Revenue, 12 months$72M$99.3B
Net income, 12 months-$40M$16.1B
Free cash flow, 12 months-$35M$20.6B
Earnings per share, 12 months-$1.13$6.59
Revenue growth, year on year85.9%6.1%
Revenue growth a year, past+85.9%over 1 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CARLJNJ
Margins and returns on capital
Gross margin77.0%67.6%
Operating margin-59.0%–
Net margin-55.8%16.2%
ROIC-31.3%12.4%
ROE-43.8%19.7%

Balance sheet

CARLJNJ
Balance sheet
Cash$60M$17.2B
Total debt$22M$44.7B
Net debt / EBITDA–1.1
Interest cover-33.3×18.0×

Dividends and buybacks

CARLJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CARL or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Carlsmed or Johnson & Johnson?

By market value, Johnson & Johnson ($644B) is about 1,396.6 times Carlsmed ($461M), at today's prices.

How did CARL and JNJ stock do over the last 1 years?

Since November 18, 2025, CARL's price moved +40.8% and JNJ's +33.6%. With dividends: CARL +40.8% (+40.8% a year), JNJ +36.6% (+36.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, CARL or JNJ?

The dividend yield at today's price is none for Carlsmed and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Carlsmed or Johnson & Johnson?

Over the last twelve months, the net margin was -55.8% for Carlsmed and 16.2% for Johnson & Johnson, and the operating margin -59.0% and –. Revenue was $72M and $99.3B.

Which is the better investment, Carlsmed or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.